finance
Outlook Therapeutics Announces $5 Million Registered Direct Offering
Outlook Therapeutics has announced a $5 million registered direct offering priced at $0.31 per share, including warrants. The offering is expected to close on April 23, 2026. This move provides the company with additional capital through a direct sale of securities.
Apr 22, 8:48 AM·1m read2 sources
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Outlook Therapeutics, a biopharmaceutical company, announced a registered direct offering to raise $5 million. The offering is priced at $0.31 per share and includes warrants. com, the closing is expected on April 23, 2026. A registered direct offering allows a company to sell securities directly to investors without a traditional underwritten public offering.
This method can provide quicker access to capital. The terms include shares and warrants, which give buyers the right to purchase additional shares at a set price in the future.
The pricing is described as at-the-market, meaning it reflects current market conditions. Outlook Therapeutics trades under the ticker OTLK. The funds from this offering could support the company's operations or development activities, though specific uses were not detailed in the announcement.
The transaction is set to close one day after the announcement, on April 23, 2026. This follows the company's disclosure on April 22, 2026. No further details on participating investors were provided in the report.
